Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.77 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.54 |
| ▸ | ASF1A | Q9Y294 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5384360 | 0.93 | MCHR1 (0.77) | MCHR1MCHR2ASF1ABCHEACHE | |
| SCHEMBL5381660 | 0.88 | MCHR1 (0.73) | MCHR1MCHR2ASF1ABCHEACHE | |
| SCHEMBL5383234 | 0.87 | MCHR1 (0.73) | MCHR1MCHR2ASF1ABCHEACHE | |
| SCHEMBL6645493 | 0.83 | MCHR1 (0.53) | MCHR1MCHR2 | |
| SCHEMBL5385461 | 0.82 | MCHR1 (0.77) | MCHR1ASF1ABCHEACHEKDR | |
| SCHEMBL5254707 | 0.79 | MCHR1 (0.61) | MCHR1ASF1ABCHEACHEKDR | |
| SCHEMBL5396612 | 0.79 | MCHR1 (0.59) | MCHR1ASF1ABCHEACHEKDR | |
| SCHEMBL5389988 | 0.76 | MCHR1 (0.72) | MCHR1ASF1ABCHEACHEKDR | |
| SCHEMBL6646036 | 0.76 | MCHR1 (0.53) | MCHR1MCHR2 | |
| SCHEMBL14399534 | 0.76 | MCHR1 (0.76) | MCHR1ASF1ABCHEACHEKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220777-B2 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-05-22 | — | — | US | disclosed |
| EP-1436267-B1 | LACTAM DERIVATIVES AS ANTAGONISTS FOR HUMAN 11CBY RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-20060287321-A1 | Novel Lactam Derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-21 | — | — | US | disclosed |
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059651-A1 | Lactam derivatives as antagonists for human 11cby receptors | ADRB3, GPR3, ADRB1 | MCHR1 433/4885MCHR2 583/4885ASF1A 4753/4885 |
| US-20060287321-A1 | Novel Lactam Derivatives | MRPL21, PEPD, STS | MCHR1 4695/4885MCHR2 4651/4885ASF1A 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.